[ad_1]
Anti-HIV preventive treatment (PrEP) had, in one year in the Paris region, a total effectiveness, with zero infections, said Tuesday two health authorities.
Pre-exposure prophylaxis, which consists in taking Truvada (Gilead Laboratory) or its generics is for use by individuals at risk
The National Agency for Research on AIDS (ANRS) and the Paris Public Assistance-Hospitals (AP-HP) follow 1,435 volunteers "recruited between May 3, 2017 and May 1, 2018."
Zero contamination
"To date, no cases of HIV infection have been observed," said the institutions in a statement, when presenting these preliminary results to the International AIDS Conference in Amsterdam
Another encouraging result: "there has been, so far, no discontinuation of the study for reasons related to undesirable effects of treatment". This study confirms that the drug is very well tolerated.
Truvada is a simple daily choice (as do 44% of volunteers in this study) or in anticipation of badual activity (53 % volunteers). This preventive use is not his first indication: initially, this drug combining two antiretrovirals was intended for HIV-positive people.
It benefits in France from a temporary recommendation of use for its preventive use. The group of volunteers is composed "for the moment essentially of men having bad with men", emphasized the ANRS and the AP-HP.
The researchers would like "also to recruit volunteers from other populations such as transgender people and heterobadual men and women at high risk of HIV infection, "said one of them, Jean-Michel Molina (Saint-Louis Hospital in Paris). The AIDS prevention badociation AIDES supports the study in the Paris region.
Source link
